{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18"],"submitter":["Ben Khaled N"],"pubmed_abstract":["<h4>Background</h4>Immune checkpoint inhibitor (ICI)-based combination therapy has transformed the therapeutic landscape of advanced hepatocellular carcinoma (aHCC). However, durable clinical benefit remains limited to a subset of patients, highlighting the need for approaches that enhance efficacy.<h4>Objectives</h4>The MONTBLANC study presents a novel investigational strategy utilizing triple immunotherapy through the combination of the anti-programmed cell death ligand 1 antibody durvalumab, the anti-cytotoxic T-lymphocyte-associated antigen-4 tremelimumab, and the anti-vascular endothelial growth factor bevacizumab in patients with aHCC.<h4>Methods and analysis</h4>This randomized, open-label, phase II clinical trial examines two distinct therapeutic regimens through parallel study arm"],"journal":["Therapeutic advances in medical oncology"],"pagination":["17588359261417640"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12925018"],"repository":["biostudies-literature"],"pubmed_title":["Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass)."],"pmcid":["PMC12925018"],"pubmed_authors":["Chater J","Weinmann A","Masi G","Ben Khaled N","Auriemma A","Schwald I","Beyer G","Vivaldi C","Perkhofer L","Geier A","Weiss L","Kubisch I","Oehrle B","Ehmer U","Gonzalez-Carmona MA","Bauer U","von Felden J","Mayerle J","De Rosa A","Ricke J","Basch M","Antonuzzo L","Schneider JS","Piseddu I","Foerster F","Zhou T","Huwer T","De Toni EN","Seidensticker M","Daniele B","Enssle S","Altenhofer J","Ondrejkova K","Reiter FP","Ettrich TJ","Schulze K","Philipp A","Groper MN","Solda C","Karin M"],"additional_accession":[]},"is_claimable":false,"name":"Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).","description":"<h4>Background</h4>Immune checkpoint inhibitor (ICI)-based combination therapy has transformed the therapeutic landscape of advanced hepatocellular carcinoma (aHCC). However, durable clinical benefit remains limited to a subset of patients, highlighting the need for approaches that enhance efficacy.<h4>Objectives</h4>The MONTBLANC study presents a novel investigational strategy utilizing triple immunotherapy through the combination of the anti-programmed cell death ligand 1 antibody durvalumab, the anti-cytotoxic T-lymphocyte-associated antigen-4 tremelimumab, and the anti-vascular endothelial growth factor bevacizumab in patients with aHCC.<h4>Methods and analysis</h4>This randomized, open-label, phase II clinical trial examines two distinct therapeutic regimens through parallel study arm","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026","modification":"2026-07-16T18:47:48.355Z","creation":"2026-07-12T03:07:54.199Z"},"accession":"S-EPMC12925018","cross_references":{"pubmed":["41732658"],"doi":["10.1177/17588359261417640"]}}